Refine
Has Fulltext
- yes (11)
Is part of the Bibliography
- yes (11)
Document Type
- Journal article (7)
- Preprint (4)
Language
- English (11)
Keywords
- PET (6)
- Positronen-Emissions-Tomografie (6)
- prostate cancer (5)
- RADS (4)
- 18F-DCFPyL (3)
- PSMA (3)
- PSMA-RADS (3)
- Prostate Cancer (3)
- prostate-specific membrane antigen (3)
- PSMA-PET (2)
- Positron Emission Tomography (2)
- SSTR (2)
- Virchow Node (2)
- positron emission tomography (2)
- reporting and data system (2)
- 18F-DCFPL (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- GI (1)
- Ganglia (1)
- Gastrointestinal (1)
- Gleason score (1)
- Imaging pitfalls (1)
- MI-RADS (1)
- Neuroendocrine (1)
- Neuroendocrine Tumor (1)
- Oncology (1)
- PET/CT (1)
- PROMISE (1)
- PRRT (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-targeted PET (1)
- Pitfall (1)
- Prostata (1)
- Radionuclide Therapy (1)
- Radiotracer (1)
- SSTR-RADS (1)
- SUV (1)
- Standardisierung (1)
- Tracer (1)
- \(^{18}\)F-DCFPyL PET/CT (1)
- interobserver (1)
- interreader (1)
- neuroendocrine neoplasia (1)
- neuroendocrine tumor (1)
- personalized medicine (1)
- prostate-specific antigen (1)
- prostate-specific membrane antigen (PSMA) (1)
- reporting and data systems (1)
- somatostatin receptor (1)
- somatostatin receptor (SSTR) (1)
- standardization (1)
- standardized reporting (1)
- theranostics (1)
Institute
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (8)
Reliable standards and criteria for somatostatin receptor (SSTR) positron emission tomography (PET) are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR-PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors (NET). SSTR-RADS could guide the imaging specialist in interpreting SSTR-PET scans, facilitate communication with the referring clinician so that appropriate work-up for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned Peptide Receptor Radionuclide Therapy.